Conversely, cluster 2 (progenitor HepaRG), was significantly enriched in HCC previously defined by poor prognosis signatures, including poor survival genes [7], hepatoblast-associated genes [10] and genes associated with the activation of a pro-oncogenic MET/HGF pathway [29] and a so-called late pro-metastatic TGFβ signature [19] (Figure 4A,B). The gene discussed is MET; the disease is hepatocellular carcinoma.